Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Eli Lilly and Company-Product Pipeline Review-2015

Eli Lilly and Company-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Eli Lilly and Company-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Eli Lilly and Company-Product Pipeline Review-2015', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eli Lilly and Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Eli Lilly and Company including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Eli Lilly and Company's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Eli Lilly and Company's pipeline products

Reasons To Buy

Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Eli Lilly and Company in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Eli Lilly and Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Eli Lilly and Company and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eli Lilly and Company

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Eli Lilly and Company and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Eli Lilly and Company Snapshot 8

Eli Lilly and Company Overview 8

Key Information 8

Key Facts 8

Eli Lilly and Company-Research and Development Overview 9

Key Therapeutic Areas 9

Eli Lilly and Company-Pipeline Review 18

Pipeline Products by Stage of Development 18

Pipeline Products-Monotherapy 19

Pipeline Products-Combination Treatment Modalities 20

Pipeline Products-Partnered Products 21

Pipeline Products-Out-Licensed Products 24

Eli Lilly and Company-Pipeline Products Glance 26

Eli Lilly and Company-Late Stage Pipeline Products 26

Eli Lilly and Company-Clinical Stage Pipeline Products 29

Eli Lilly and Company-Early Stage Pipeline Products 34

Eli Lilly and Company-Unknown Stage Pipeline Products 36

Eli Lilly and Company-Drug Profiles 37

dulaglutide 37

duloxetine hydrochloride DR 40

necitumumab 42

ramucirumab 45

cetuximab 50

abemaciclib 57

baricitinib 58

evacetrapib 61

insulin peglispro 63

ixekizumab 65

LY-2951742 66

odelepran hydrochloride 67

solanezumab 68

tadalafil 70

edivoxetine 72

galunisertib 74

blosozumab 76

emibetuzumab 77

erteberel 78

insulin lispro U100 79

LY-2409021 81

LY-2495655 82

LY-2510924 83

LY-2606368 84

LY-2623091 85

LY-2928057 86

LY-2940094 87

LY-2944876 88

LY-3015014 90

LY-3016859 91

LY-3023414 92

merestinib 94

olaratumab 95

pemetrexed disodium 97

ralimetinib mesylate 103

taladegib 104

Biologic 3 for Diabetes 105

Biologic 4 for Diabetes 106

Biologic 5 for Diabetes 107

Biologic for Anemia 108

Biologic for Crohn's Disease 109

Biologic for Diabetic Nephropathy 110

Biologic for Hypoglycemia 111

Biologic for Lupus 112

Biologic for Ulcerative Colitis 113

LY-2608204 114

LY-2780301 115

LY-2874455 116

LY-2922083 117

LY-2922470 118

LY-2969822 119

LY-2979165 120

LY-3002813 121

LY-3009120 122

LY-3022855 123

LY-3022856 124

LY-3025876 125

LY-3039478 126

LY-3041658 127

LY-3045697 128

LY-3050258 129

LY-3074828 130

LY-3079514 131

LY-3084077 132

LY-3090106 133

LY-3108743 134

LY-3113593 135

LY-3114062 136

LY-3127760 137

LY-3143753 138

LY-3154207 139

LY-3164530 140

LY-3185643 141

LY-3202626 142

LY-900014 143

Small Molecule for Hypertension 144

Small Molecule for Muscle Atrophy 145

Small Molecule to Agonize mGlu2/3 for Chronic Pain 146

cercosporamide 147

CPZEN-45 149

insulin lispro U200 150

insulin lispro U300 151

LLY-2707 152

LSN-2463359 153

LSN-2535717 154

LSN-2814617 155

LY-2109761 156

LY-2607540 157

LY-2857785 158

LY-3002813 + LY-2811376 159

Monoclonal Antibody Conjugate 1 for Cancer 160

Monoclonal Antibody Conjugate 2 for Cancer 161

Monoclonal Antibody Conjugate 3 for Cancer 162

ND-09759 163

Peptide for Type 2 Diabetes and Obesity 164

Small Molecule to Agonize TR-Beta for Dyslipidemia 165

Small Molecule to Antagonize mGlu5 for Pain 166

Monoclonal Antibodies for Cancer 167

Monoclonal Antibodies for Undisclosed Indication 168

Monoclonal Antibody Conjugates for Cancer 169

Small Molecule for Type 2 Diabetes 170

Small Molecules to Inhibit Beta Secretase for Alzheimer's Disease 171

LY-3000328 172

Eli Lilly and Company-Pipeline Analysis 173

Eli Lilly and Company-Pipeline Products by Target 173

Eli Lilly and Company-Pipeline Products by Route of Administration 179

Eli Lilly and Company-Pipeline Products by Molecule Type 180

Eli Lilly and Company-Pipeline Products by Mechanism of Action 181

Eli Lilly and Company-Recent Pipeline Updates 187

Eli Lilly and Company-Dormant Projects 214

Eli Lilly and Company-Discontinued Pipeline Products 218

Discontinued Pipeline Product Profiles 220

Eli Lilly and Company-Company Statement 229

Eli Lilly and Company-Locations And Subsidiaries 233

Head Office 233

Other Locations & Subsidiaries 233

Eli Lilly and Company-Key Manufacturing Facilities 241

Appendix 242

Methodology 242

Coverage 242

Secondary Research 242

Primary Research 242

Expert Panel Validation 242

Contact Us 242

Disclaimer 243

List of Tables

Eli Lilly and Company, Key Information 16

Eli Lilly and Company, Key Facts 16

Eli Lilly and Company-Pipeline by Indication, 2015 19

Eli Lilly and Company-Pipeline by Stage of Development, 2015 26

Eli Lilly and Company-Monotherapy Products in Pipeline, 2015 27

Eli Lilly and Company-Combination Treatment Modalities in Pipeline, 2015 28

Eli Lilly and Company-Partnered Products in Pipeline, 2015 29

Eli Lilly and Company-Partnered Products/ Combination Treatment Modalities, 2015 30

Eli Lilly and Company-Out-Licensed Products in Pipeline, 2015 32

Eli Lilly and Company-Out-Licensed Products/ Combination Treatment Modalities, 2015 33

Eli Lilly and Company-Pre-Registration, 2015 34

Eli Lilly and Company-Filing rejected/Withdrawn, 2015 35

Eli Lilly and Company-Phase III, 2015 36

Eli Lilly and Company-Phase II, 2015 37

Eli Lilly and Company-Phase I, 2015 39

Eli Lilly and Company-Preclinical, 2015 42

Eli Lilly and Company-Discovery, 2015 43

Eli Lilly and Company-Unknown, 2015 44

Eli Lilly and Company-Pipeline by Target, 2015 182

Eli Lilly and Company-Pipeline by Route of Administration, 2015 187

Eli Lilly and Company-Pipeline by Molecule Type, 2015 188

Eli Lilly and Company-Pipeline Products by Mechanism of Action, 2015 189

Eli Lilly and Company-Recent Pipeline Updates, 2015 195

Eli Lilly and Company-Dormant Developmental Projects,2015 222

Eli Lilly and Company-Discontinued Pipeline Products, 2015 226

Eli Lilly and Company, Subsidiaries 241

Eli Lilly and Company, Key Manufacturing Facilities 249

List of Figures

Eli Lilly and Company-Pipeline by Top 10 Indication, 2015 18

Eli Lilly and Company-Pipeline by Stage of Development, 2015 26

Eli Lilly and Company-Monotherapy Products in Pipeline, 2015 27

Eli Lilly and Company-Partnered Products in Pipeline, 2015 29

Eli Lilly and Company-Out-Licensed Products in Pipeline, 2015 32

Eli Lilly and Company-Pipeline by Top 10 Target, 2015 181

Eli Lilly and Company-Pipeline by Top 10 Route of Administration, 2015 187

Eli Lilly and Company-Pipeline by Top 10 Molecule Type, 2015 188

Eli Lilly and Company-Pipeline Products by Top 10 Mechanism of Action, 2015 189

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Eli Lilly and Company; Eli Lilly and Company - Key Therapeutics; Eli Lilly and Company - Pipeline Overview and Promising Molecules; Eli Lilly and Company - News; Eli Lilly and Company - Latest Updates; Eli Lilly and Company - Pipeline; Eli Lilly and Company - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com